Home › Trial NCT02259114
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
- Trial IDNCT02259114
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorOncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Enrollment47
- Start date2014-10-23
- ConditionsNUT Midline Carcinoma · Triple Negative Breast Cancer · Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation · Castrate-resistant Prostate Cancer · CRPC · Pancreatic Ductal Adenocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.